Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10497611 | 0.95 | SMPD1 (0.48) | TSHRL3MBTL1THRATHRBHPGD | |
| SCHEMBL14068399 | 0.93 | SMPD1 (0.50) | THRATHRBHPGDSMPD1 | |
| SCHEMBL10497856 | 0.93 | SMPD1 (0.50) | THRATHRBHPGDSMPD1 | |
| SCHEMBL10497691 | 0.93 | SMPD1 (0.50) | THRATHRBHPGDSMPD1 | |
| SCHEMBL10497889 | 0.93 | SMPD1 (0.50) | THRATHRBHPGDSMPD1 | |
| SCHEMBL10498877 | 0.93 | SMPD1 (0.50) | THRATHRBHPGDSMPD1 | |
| SCHEMBL10498337 | 0.93 | SMPD1 (0.50) | THRATHRBHPGDSMPD1 | |
| SCHEMBL15680517 | 0.89 | THRA (0.42) | SLC6A5L3MBTL1GAATHRATHRB | |
| SCHEMBL7995915 | 0.86 | PLA2G2A (0.56) | TSHRTHRATHRBHPGD | |
| SCHEMBL6418870 | 0.84 | THRA (0.46) | TSHRSLC6A5THRATHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017006048-A1 | VICINAL PRIMARY DIAMINES ASSOCIATED WITH METAL AND/OR FREE RADICAL CHELATION MOTIFS, AND ACTIVE AGAINST CARBONYL AND OXIDATIVE STRESS, AND USE THEREOF | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2017-01-12 | — | — | WO | disclosed |
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2016-05-19 | — | — | US | disclosed |
| US-9181162-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-8754052-B2 | Treatment of nephrolithiasis and urolithiasis using 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-8513395-B2 | Method for the synthesis of anthocyanins | BIOSYNTH AS (NO) | 2013-08-20 | — | — | US | disclosed |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2009158487-A2 | TREATMENT OF NEPHROLITHIASIS AND UROLITHIASIS USING 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOSE (PGG) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2009-04-30 | — | — | US | disclosed |
| EP-0328669-A1 | CHALCONE DERIVATIVE COMPOUNDS | NIPPON OIL AND FATS COMPANY, LIMITED (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | TSHR 3470/4885SLC6A5 556/4885L3MBTL1 2135/4885 |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | TSHR 3470/4885SLC6A5 556/4885L3MBTL1 2135/4885 |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | POR, SPR, G6PD | TSHR 4373/4885SLC6A5 1930/4885L3MBTL1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.